Cypress Capital Group Bristol Myers Squibb CO Transaction History

Cypress Capital Group

$879 Million
Q3 2024

A detailed history of Cypress Capital Group transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Cypress Capital Group holds 74,876 shares of BMY stock, worth $4.32 Million. This represents 0.44% of its overall portfolio holdings.

Number of Shares

74,876

Previous 99,081 24.43%

Holding current value

$4.32 Million

Previous $4.11 Million 5.83%

% of portfolio

0.44%

Previous 0.5%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$39.66 - $51.75 $959,970 - $1.25 Million	-24,205 Reduced 24.43%	74,876 $3.87 Million
Q2 2024 Jul 25, 2024	SELL	$40.25 - $52.99 $76,958 - $101,316	-1,912 Reduced 1.89%	99,081 $4.11 Million
Q1 2024 May 08, 2024	BUY	$47.98 - $54.4 $83,725 - $94,928	1,745 Added 1.76%	100,993 $5.48 Million
Q4 2023 Jan 24, 2024	BUY	$48.48 - $57.85 $54,588 - $65,139	1,126 Added 1.15%	99,248 $5.09 Million
Q3 2023 Nov 02, 2023	SELL	$57.89 - $64.73 $79,540 - $88,939	-1,374 Reduced 1.38%	98,122 $5.7 Million
Q2 2023 Jul 26, 2023	SELL	$63.71 - $70.74 $624,676 - $693,605	-9,805 Reduced 8.97%	99,496 $6.36 Million
Q1 2023 May 04, 2023	SELL	$65.71 - $74.53 $549,795 - $623,592	-8,367 Reduced 7.11%	109,301 $7.58 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $188,730 - $223,484	2,756 Added 2.4%	117,668 $8.47 Million
Q3 2022 Nov 04, 2022	BUY	$0.13 - $76.84 $877 - $518,439	6,747 Added 6.24%	114,912 $8.17 Million
Q2 2022 Jul 26, 2022	SELL	$72.62 - $79.98 $67,827 - $74,701	-934 Reduced 0.86%	108,165 $8.33 Million
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $599,983 - $719,433	9,759 Added 9.82%	109,099 $7.97 Million
Q4 2021 Feb 15, 2022	BUY	$53.63 - $62.52 $407,802 - $475,402	7,604 Added 8.29%	99,340 $6.19 Million
Q3 2021 Oct 12, 2021	SELL	$59.17 - $69.31 $79,524 - $93,152	-1,344 Reduced 1.44%	91,736 $5.43 Million
Q2 2021 Jul 13, 2021	SELL	$61.91 - $67.42 $331,404 - $360,899	-5,353 Reduced 5.44%	93,080 $6.22 Million
Q1 2021 Apr 14, 2021	SELL	$59.34 - $66.74 $788,569 - $886,907	-13,289 Reduced 11.89%	98,433 $6.21 Million
Q4 2020 Jan 12, 2021	SELL	$57.74 - $65.43 $306,426 - $347,237	-5,307 Reduced 4.53%	111,722 $6.93 Million
Q3 2020 Oct 08, 2020	BUY	$57.43 - $63.64 $227,193 - $251,759	3,956 Added 3.5%	117,029 $7.06 Million
Q2 2020 Jul 10, 2020	BUY	$54.82 - $64.09 $332,483 - $388,705	6,065 Added 5.67%	113,073 $6.65 Million
Q1 2020 Apr 08, 2020	SELL	$46.4 - $67.43 $18,420 - $26,769	-397 Reduced 0.37%	107,008 $5.97 Million
Q4 2019 Jan 10, 2020	BUY	$49.21 - $64.19 $1.74 Million - $2.27 Million	35,304 Added 48.96%	107,405 $6.89 Million
Q3 2019 Oct 10, 2019	BUY	$42.77 - $50.71 $503,146 - $596,552	11,764 Added 19.5%	72,101 $3.66 Million
Q2 2019 Aug 15, 2019	BUY	$44.62 - $49.34 $145,862 - $161,292	3,269 Added 5.73%	60,337 $2.74 Million
Q1 2019 May 14, 2019	SELL	$45.12 - $53.8 $115,146 - $137,297	-2,552 Reduced 4.28%	57,068 $2.72 Million
Q4 2018 Feb 19, 2019	BUY	$48.76 - $63.23 $94,789 - $122,919	1,944 Added 3.37%	59,620 $3.1 Million
Q3 2018 Nov 15, 2018	SELL	$55.19 - $62.25 $77,045 - $86,901	-1,396 Reduced 2.36%	57,676 $3.58 Million
Q2 2018 Aug 15, 2018	SELL	$50.53 - $62.98 $1.09 Million - $1.35 Million	-21,484 Reduced 26.67%	59,072 $3.27 Million
Q1 2018 May 21, 2018	BUY	$59.92 - $68.98 $384,087 - $442,161	6,410 Added 8.65%	80,556 $5.1 Million
Q4 2017 Feb 14, 2018	BUY	$59.94 - $65.35 $247,252 - $269,568	4,125 Added 5.89%	74,146 $4.54 Million
Q3 2017 Nov 16, 2017	SELL	$55.23 - $63.74 $17,949 - $20,715	-325 Reduced 0.46%	70,021 $4.46 Million
Q2 2017 Aug 15, 2017	BUY	N/A	70,346	70,346 $3.92 Million

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cypress Capital Group, based on Form 13F filings with the SEC.

News

Stay updated on Cypress Capital Group with notifications on news.

Account

Cypress Capital Group Bristol Myers Squibb CO Transaction History